In contrast to the previously described TNF antagonists, several other investigational therapies targeted against TNF have failed to demonstrate efficacy in achieving or maintaining remission in CD. For example, the TNF antagonist CDP571, a humanized IgG4 monoclonal antibody, failed to demonstrate efficacy for maintenance of remission at 24-26 weeks (Sandborn et al. 2004b). The human p75 soluble TNF receptor fusion protein etanercept, as well as onercept, a recombinant form of the human soluble p55 TNF receptor, both failed to demonstrate efficacy in CD in clinical trials (Rutgeerts et al. 2004b; Sandborn et al. 2001).
Was this article helpful?
Do You Suffer From the Itching and Scaling of Psoriasis? Or the Chronic Agony of Psoriatic Arthritis? If so you are not ALONE! A whopping three percent of the world’s populations suffer from either condition! An incredible 56 million working hours are lost every year by psoriasis sufferers according to the National Psoriasis Foundation.